Canine lymphoma, a phenotypically and genetically heterogeneous disease, represents a significant proportion of canine cancers. We present a large-scale study of 238 dogs with lymphoma to better understand the genetic landscape of canine lymphoma, as well as the relationship to clinical outcomes. Using a targeted next-generation sequencing panel comprising 308 genes, we screened somatic and germline mutations in matched tumor and normal samples. Our findings revealed key associations between genetic alterations and lymphoma subtypes, with certain somatic variants linked to significant differences in response to common chemotherapy regimens. Recurrent mutations in genes such as KMT2C, KMT2D, NOTCH2, TRAF3, CCND1, ARID1A, CREBBP, and TP53 were observed, with TRAF3 mutations standing out for their significant association with prolonged progression-free survival and overall survival in B-cell lymphomas. In contrast, mutations in PIK3CD and CREBBP were associated with inferior outcomes in T-cell lymphomas, highlighting the immunophenotype-specific impact of genetic alterations on treatment responses. These findings support the integration of comprehensive genomic profiling in planning treatment strategies and optimizing clinical outcomes in canine lymphomas.
Feline lymphoma, a prevalent cancer in cats, exhibits varied prognoses influenced by anatomical site and cellular characteristics. In this study, we investigated the utility of flow cytometry and clonality analysis via PCR for antigen receptor rearrangement (PARR) with respect to characterizing the disease and predicting prognosis. For this purpose, we received fine needle aspirates and/or blood from 438 feline patients, which were subjected to flow cytometry analysis and PARR. We used a subset of the results from patients with confirmed B- or T-cell lymphomas for comparison to cytological or histological evaluation (n = 53). Using them as a training set, we identified the optimal set of flow cytometry parameters, namely forward scatter thresholds, for cell size categorization by correlating with cytology-defined sizes. Concordance with cytological sizing among this training set was 82%. Furthermore, 90% concordance was observed when the proposed cell sizing was tested on an independent test set (n = 24), underscoring the reliability of the proposed approach. Additionally, lymphoma subtypes defined by flow cytometry and PARR demonstrated significant survival differences, validating the prognostic utility of these methods. The proposed methodology achieves high concordance with cytological evaluations and provides an additional tool for the characterization and management of feline lymphoproliferative diseases.